title: Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
abstract: Fibrate derivatives and HMG-CoA reductase inhibitors modify homeostasis of cholesterol. The aim of this study was to assess in an unselected population whether these hypolipidemic drugs are risk factors for cholelithiasis or, conversely, are protective agents. Both sexes, all socioeconomic categories, pregnant women, and cholecystectomized subjects were included. Clinical data collection and gallbladder ultrasonography were both carried out in a double-blind fashion. Fibrate derivatives were predominantly fenofibrate, HMG-CoA reductase inhibitors were simvastatin and pravastatin. On univariate analysis, age (>50 years), sex, and use of fibrates were found to be significantly related to the presence of cholelithiasis. Age, sex, and fibrate treatment remained independently correlated with the presence of gallstones on multivariate analysis. With fibrates, the relative risk for lithiasis was 1.7 (P = 0.04). The HMG-CoA reductase inhibitors were not associated with a protective effect on univariate analysis. Of the lipid-lowering drugs, only fibrate derivatives were found to increase the risk of gallstone formation.
authors.affiliation: Federation of Digestive Diseases, Archet II Hospital, University of Nice-Sophia, Antipolis, France.
authors.forename: F X
authors.initials: FX
authors.lastname: Caroli-Bosc
authors.forename: P
authors.initials: P
authors.lastname: Le Gall
authors.forename: P
authors.initials: P
authors.lastname: Pugliese
authors.forename: B
authors.initials: B
authors.lastname: Delabre
authors.forename: C
authors.initials: C
authors.lastname: Caroli-Bosc
authors.forename: J F
authors.initials: JF
authors.lastname: Demarquay
authors.forename: J P
authors.initials: JP
authors.lastname: Delmont
authors.forename: P
authors.initials: P
authors.lastname: Rampal
authors.forename: J C
authors.initials: JC
authors.lastname: Montet
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000494:pharmacology; D002769:Cholelithiasis / Q000139:chemically induced* / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000009:adverse effects* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000009:adverse effects* / Q000494:pharmacology; D011247:Pregnancy; D012307:Risk Factors; D019821:Simvastatin / Q000009:adverse effects* / Q000494:pharmacology
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D019821:Simvastatin; D017035:Pravastatin; D011345:Fenofibrate